SCHEMBL12599208

SCHEMBL12599208

Cc1ccc(C(=O)N(C)C)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.49
RAB9A P51151 2/20 0.49
HPGD P15428 2/20 0.49
SLC6A2 P23975 3/20 0.47
SLC6A4 P31645 3/20 0.47
SLC6A3 Q01959 3/20 0.47
CHRNA1 P02708 1/20 0.47
CHRNG P07510 1/20 0.47
CHRNB1 P11230 1/20 0.47
CHRNB2 P17787 1/20 0.47
CHRNB4 P30926 1/20 0.47
CHRNA3 P32297 1/20 0.47
CHRNA4 P43681 1/20 0.47
CHRND Q07001 1/20 0.47
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAPK11 Q15759 1/20 0.45
HSP90AA1 P07900 2/20 0.45
HSP90AB1 P08238 2/20 0.45
KCNH2 Q12809 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8988251 0.82 MLYCD (0.45) NPC1RAB9AHPGDSLC6A2SLC6A4
SCHEMBL12051807 0.82 SMN1; SMN2 (0.52) NPC1RAB9AHPGDALDH1A1SMN1; SMN2
SCHEMBL15709079 0.81 SLC6A2 (0.43) HPGDSLC6A2SLC6A4SLC6A3ALDH1A1
SCHEMBL29421591 0.81 SLC6A2 (0.43) HPGDSLC6A2SLC6A4SLC6A3ALDH1A1
SCHEMBL3787476 0.81 ALDH1A1 (0.51) NPC1RAB9AHPGDSLC6A2SLC6A4
SCHEMBL355700 0.81 HSP90AA1 (0.67) HPGDALDH1A1SMN1; SMN2HSP90AA1HSP90AB1
SCHEMBL9686186 0.80 HSP90AA1 (0.71) HPGDSLC6A2SLC6A4SLC6A3CHRNA1
SCHEMBL2924706 0.79 HPGD (0.54) NPC1RAB9AHPGDSLC6A2SLC6A4
SCHEMBL15709090 0.79 ALDH1A1 (0.50) NPC1RAB9AHPGDSLC6A2SLC6A4
SCHEMBL1782199 0.79 GPBAR1 (0.48) HPGDSLC6A2SLC6A4SLC6A3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022118966-A1 AGENT FOR PROMOTING NUCLEIC ACID MOLECULE UPTAKE INTO CELLS, PHARMACEUTICAL COMPOSITION, AND NOVEL COMPOUND 国立大学法人京都大学 2022-06-09 WO disclosed
EP-2421871-B1 THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INT (DE) 2015-09-16 EP disclosed
US-8288379-B2 Thia-triaza-cyclopentazulenes BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-16 US disclosed
US-20110112087-A1 Thia-triaza-cyclopentazulenes BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112087-A1 Thia-triaza-cyclopentazulenes CCNA1, MKI67, CCNT1 NPC1 686/4885RAB9A 1011/4885HPGD 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.